MYLAN'S TOLMETIN APPROVED IN USA
Mylan Laboratories has received approval from the US Food and Drug Administration to manufacture and market a generic version of McNeil's Tolecton (tolmetin sodium). McNeil is a subsidiary of Johnson & Johnson.
Tolmetin is a non-steroidal anti-inflammatory drug which is widely-used in the treatment of rheumatoid arthritis and osteoarthritis. The approval is for a 400mg capsule formulation of tolmetin, according to Mylan.
Sales of the branded version of tolmetin are in the region of about $70 million a year, although Mylan is not the first generics company to get approval for a non-branded form A version developed by IVAX Pharmaceuticals was approved by the FDA a few months ago. Tolmetin lost its patent protection in 1992.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze